PrimeCell™ VP of R&D to Discuss Adult Pluripotent Stem Cell Advances
News Jun 16, 2006
PrimeCell™ Therapeutics has announced that its Vice President of Research and Development, Francisco Silva, has been invited to participate in a panel discussion hosted by Sen. Rick Santorum (R-PA) to discuss the Alternative Pluripotent Stem Cells Therapies Enhancement Act (S.2754), which would intensify research into alternative methods of deriving pluripotent stem cells.
PrimeCell Therapeutics' platform allows for the reprogramming of adult germ-line stem cells-PrimeCells-the company's pluripotent proprietary cell line capable of transforming into any cell type.
PrimeCell has already been reprogrammed into heart, nerve, bone and cartilage cells and holds promise for expediting the process from research to therapy.
WHO: Francisco J. Silva, Vice President of Research & Development for PrimeCell Therapeutics.
Silva is a principal contributor to the company's intellectual property portfolio and oversees the development of all therapeutic platforms.
He is responsible for PrimeCell Therapeutics' current scientific progress and designs, and also implements the company's premier research developments.
WHAT: PrimeCell Therapeutics LLC, a recently formed subsidiary of PrimeGen Biotech LLC, is devoted exclusively to adult stem cell reprogramming.
The company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences.
WHEN: 10:00 am Thursday, June 15th, 2006
WHERE: S-120 U.S. Capitol Building
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.